ストックスクリーナーアプリを入手
7.27
0.68%
-0.05
アフターアワーズ：
7.35
0.08
+1.10%
前日終値:
$7.32
開ける：
$7.3
24時間の取引高:
861.42K
Relative Volume:
0.38
時価総額：
$429.72M
収益：
$216.11M
当期純損益:
$-220.47M
株価収益率:
-1.9458
EPS:
-3.7363
ネットキャッシュフロー:
$-110.44M
1週間 パフォーマンス:
-0.27%
1か月 パフォーマンス:
-17.48%
6か月 パフォーマンス:
+35.13%
1年 パフォーマンス:
+66.36%
1日の値動き範囲:
$7.20
$7.40
1週間の範囲:
$7.0597
$7.42
52週間の値動き範囲:
$3.8092
$9.94
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
名前
Vanda Pharmaceuticals Inc
セクター
電話
202-734-3400
住所
2200 PENNSYLVANIA AVE NW, WASHINGTON
Compare VNDA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
7.27 | 432.67M | 216.11M | -220.47M | -110.44M | -3.7363 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-05 | 開始されました | Truist | Buy |
| 2025-11-05 | 開始されました | B. Riley Securities | Buy |
| 2024-10-31 | 開始されました | H.C. Wainwright | Buy |
| 2024-07-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-02-25 | ダウングレード | Jefferies | Buy → Hold |
| 2021-05-12 | 開始されました | BofA Securities | Buy |
| 2021-01-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-10-29 | アップグレード | Citigroup | Neutral → Buy |
| 2020-06-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-03-16 | ダウングレード | Oppenheimer | Perform → Underperform |
| 2020-03-12 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-07 | ダウングレード | Citigroup | Buy → Neutral |
| 2019-08-01 | アップグレード | Citigroup | Neutral → Buy |
| 2019-07-25 | ダウングレード | Stifel | Buy → Hold |
| 2018-12-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2018-12-04 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | 繰り返されました | Jefferies | Buy |
| 2018-11-08 | 再開されました | Jefferies | Buy |
| 2018-09-21 | 再開されました | Oppenheimer | Outperform |
| 2018-05-23 | 開始されました | Citigroup | Buy |
| 2018-01-19 | 開始されました | Seaport Global Securities | Buy |
| 2017-09-14 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-06-27 | 再開されました | Piper Jaffray | Overweight |
| 2017-05-26 | 開始されました | H.C. Wainwright | Buy |
| 2017-04-12 | 開始されました | Oppenheimer | Outperform |
| 2016-11-09 | 開始されました | Aegis Capital | Buy |
| 2016-10-06 | 再開されました | Jefferies | Buy |
すべてを表示
Vanda Pharmaceuticals Inc (VNDA) 最新ニュース
Scott Laverne Howell Net Worth (2026) - GuruFocus
Polymeropoulos Christos Vasilios Mihael Net Worth (2026) - GuruFocus
Vanda Pharmaceuticals (NASDAQ: VNDA) executive details stock, options and RSUs - Stock Titan
[Form 3] Vanda Pharmaceuticals Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update - MarketBeat
Vanda Pharmaceuticals Stock Price Forecast. Should You Buy VNDA? - StockInvest.us
Vanda Pharmaceuticals opposes FDA drug review timeline proposal By Investing.com - Investing.com Australia
Vanda Pharmaceuticals (VNDA) Criticizes FDA Review Process Changes - GuruFocus
Market Leaders: Should I invest in Vanda Pharmaceuticals Inc before earnings2026 Top Gainers & Technical Confirmation Alerts - baoquankhu1.vn
Vanda Pharmaceuticals opposes FDA drug review timeline proposal - Investing.com
A 180-day drug review rule could stretch to 10-12 months under FDA plan - Stock Titan
Vanda Pharmaceuticals Inc. (VNDA) Stock Price, News, Quote & History - Yahoo! Finance Canada
H.C. Wainwright reiterates Vanda Pharmaceuticals stock rating on GLP-1 trial - Investing.com Australia
Vanda initiates trial of NEREUS for GLP-1 therapy side effects By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals (VNDA) Launches Thetis Trial for Vomiting Prevention - GuruFocus
Vanda initiates trial of NEREUS for GLP-1 therapy side effects - Investing.com Australia
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - Finviz
Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of Nereus™ For The Prevention Of Vomiting Induced By Glp-1 Receptor Agonists - TradingView — Track All Markets
Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists - Nasdaq
Options Flow: What is the target price for Vanda Pharmaceuticals Inc stockWeekly Trend Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Rate Cut: Is Vanda Pharmaceuticals Inc affected by consumer sentimentStop Loss & Consistent Income Trade Recommendations - baoquankhu1.vn
Downgrade Watch: Can Vanda Pharmaceuticals Inc ride the EV waveDip Buying & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Vanda Announces Resignation of Senior Legal Executive - The Globe and Mail
Vanda Pharmaceuticals executive Timothy Williams to resign as general counsel - Investing.com Australia
Timothy Williams resigns as Senior Vice President, General Counsel and Secretary at Vanda - TradingView — Track All Markets
Vanda Pharmaceuticals Inc. Announces Resignation of Timothy Williams as Senior Vice President, General Counsel and Secretary, Effective April 10, 2026 - marketscreener.com
Vanda Pharmaceuticals (NASDAQ: VNDA) general counsel resigns role - Stock Titan
Vanda Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Aug Levels: Can Vanda Pharmaceuticals Inc ride the EV wavePortfolio Return Report & Low Risk Investment Opportunities - baoquankhu1.vn
Pullback Watch: Will Vanda Pharmaceuticals Inc outperform tech stocksRate Cut & Reliable Momentum Entry Alerts - baoquankhu1.vn
VNDA Technical Analysis & Stock Price Forecast - Intellectia AI
Vanguard disaggregates holdings; reports 0 shares of Vanda Pharmaceuticals (VNDA) - Stock Titan
Truist reiterates Vanda Pharmaceuticals stock rating after EMA decision By Investing.com - Investing.com Canada
Vanda Pharmaceuticals stock faces institutional dominance amid biotech sector volatility and retail - AD HOC NEWS
Gastroparesis Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharma - Barchart
Gastroparesis Pipeline 2026: FDA Updates, Therapy - openPR.com
Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) added to S&P Biotechnology Select Industry Index - MarketScreener
Vanda Pharmaceuticals Faces New Market Challenges Amid Share Sale and Regulatory Roadblocks - timothysykes.com
If You Invested $1,000 in Vanda Pharma (VNDA) - Stock Titan
Insider Sell: Can Vanda Pharmaceuticals Inc ride the EV wave2026 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO’s Significant Stock Sale Raises Concerns for Vanda Pharmaceuticals - timothysykes.com
Vanda Pharmaceuticals Faces Shareholder Movements and Regulatory Setbacks - StocksToTrade
Vanda Pharmaceuticals Inc. (VNDA) latest stock news and headlines - Yahoo Finance Singapore
Vanda stock draws heavy buzz ahead of FDA verdict on Bysanti for bipolar, schizophrenia - MSN
Vanda Pharmaceuticals Raises Concerns Over FDA's New Guidance on Drug Development - Intellectia AI
VNDA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
What's going on with Vanda Pharma stock Tuesday? - MSN
Vanda Pharmaceuticals Faces Setbacks as CEO Mihael Polymeropoulos Sells Shares - StocksToTrade
Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerat - GuruFocus
Vanda Pharmaceuticals urges FDA to accelerate move away from animal testing - Traders Union
Vanda Pharmaceuticals Inc (VNDA) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):